Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021

    Author microcapwatchPosted on Categories BiotechTags , , , , , , , , , , , , , ,

    BASKING RIDGE, N.J., May 04, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events:


    About Caladrius Biosciences

    Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

    The Company’s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12), recipient of  orphan designation for Buerger’s Disease in the U.S. as well as  SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s Disease based on the results of an ongoing clinical trial; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (“DKD”); and OLOGO™ (CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company is in discussion with the FDA to finalize a Phase 3 protocol of reduced size and scope for a confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”).  For more information on the Company, please visit

    www.caladrius.com

    .


    Contact:


    Investors:


    Caladrius Biosciences, Inc.

    John Menditto

    Vice President, Investor Relations and Corporate Communications

    Phone: +1-908-842-0084

    Email:

    [email protected]


    Media:


    Real Chemistry

    Kelly Wakelee

    Phone: 610.639.2774

    Email:

    [email protected]



    Primary Logo

    GlobeNewswire
    May 4, 2021 – 6:00 AM PDT